This announcement is a separate document:
康諾亞-B：自願性公告司普奇拜單抗注射液III期臨床試驗長期療效及安全性數據於2024年歐洲過敏及臨床免疫學會(EAACI)年會發佈
KEYMED BIO-B: VOLUNTARY ANNOUNCEMENTLONG-TERM EFFICACY AND SAFETY DATA FROM A PHASE IIICLINICAL TRIAL OF STAPOKIBART INJECTION AT THEEUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY(EAACI) CONGRESS 2024
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.